Anxiety Disorders Clinical Trial
Official title:
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Verified date | March 2023 |
Source | Trustees of Dartmouth College |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The majority of opioid users meet criteria for anxiety and depressive disorders, but most substance use disorder treatment programs do not offer treatment for co-occurring mental health problems. Anxiety and depression may also be directly linked to opioid use itself. Although treatments have been developed for anxiety and depressive symptoms for opioid users within face-to-face settings, few treatment facilities offer these in-person interventions due to their high cost and time burden. Given the deficits in research on treatments for anxiety and depression among those with opioid use disorder, the current research will examine the efficacy of a digital intervention designed to treat anxiety and depressive symptoms by augmenting the state of the science medication-based opioid use disorder treatment. Over the course of the proposed study, the research team will design and test the feasibility and acceptability of a standalone mobile intervention designed to treat persons receiving medication treatment for opioid use disorder. Participants receiving medication treatment for opioid use disorder will be randomized to receive a digital intervention to treat anxiety and depression or care as usual for a total of four weeks. The overarching goal of the proposed work is to test the feasibility and acceptability of the proposed mobile intervention. The Investigators will also explore the preliminary efficacy by examining reductions in anxiety and depressive symptoms and opioid cravings and use. This work could lead to a low-cost scalable solution to augment gold-standard treatment as usual in opioid use disorder by decreasing levels of comorbidity of anxiety and depressive disorders, thereby ultimately improving the outcomes of opioid use disorder itself.
Status | Completed |
Enrollment | 63 |
Est. completion date | March 1, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults (age 18 or older) - fluent in English - able to provide informed consent - meet current criteria for OUD (as defined by a Rapid Opioid Dependence Screen) - are receiving methadone, buprenorphine, and/or naltrexone for OUD - meet current criteria for an anxiety and/or depressive disorder (based on the Patient Health Questionnaire and the Generalized Anxiety Disorder Questionnaire). Exclusion Criteria: - active suicidality - psychosis - bipolar disorder |
Country | Name | City | State |
---|---|---|---|
United States | Center For Technology and Behavioral Health | Lebanon | New Hampshire |
Lead Sponsor | Collaborator |
---|---|
Trustees of Dartmouth College |
United States,
Applebaum AJ, Bullis JR, Traeger LN, O'cleirigh C, Otto MW, Pollack MH, Safren SA. Rates of mood and anxiety disorders and contributors to continued heroin use in methadone maintenance patients: A comparison by HIV status. Neurobehav HIV Med. 2010 Aug 10;2010(2):49-57. doi: 10.2147/NBHIV.S12371. — View Citation
Barry DT, Beitel M, Breuer T, Cutter CJ, Savant J, Peters S, Schottenfeld RS, Rounsaville BJ. Group-based strategies for stress reduction in methadone maintenance treatment: what do patients want? J Addict Med. 2011 Sep;5(3):181-7. doi: 10.1097/ADM.0b013e3181ee77cl. — View Citation
Bartoli F, Carra G, Brambilla G, Carretta D, Crocamo C, Neufeind J, Baldacchino A, Humphris G, Clerici M. Association between depression and non-fatal overdoses among drug users: a systematic review and meta-analysis. Drug Alcohol Depend. 2014 Jan 1;134:12-21. doi: 10.1016/j.drugalcdep.2013.10.007. Epub 2013 Oct 24. — View Citation
Blume, A. W., Schmaling, K. B., & Marlatt, G. A. (2000). Revisiting the self-medication hypothesis from a behavioral perspective. Cognitive and Behavioral Practice, 7(4), 379-384. https://doi.org/10.1016/S1077-7229(00)80048-6
Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002 Apr;70(2):288-98. — View Citation
Childress AR, Ehrman R, McLellan AT, MacRae J, Natale M, O'Brien CP. Can induced moods trigger drug-related responses in opiate abuse patients? J Subst Abuse Treat. 1994 Jan-Feb;11(1):17-23. doi: 10.1016/0740-5472(94)90060-4. — View Citation
Cunningham JA, Hendershot CS, Kay-Lambkin F, Neighbors C, Griffiths KM, Bennett K, Bennett A, Godinho A, Schell C. Does providing a brief internet intervention for hazardous alcohol use to people seeking online help for depression reduce both alcohol use and depression symptoms among participants with these co-occurring disorders? Study protocol for a randomised controlled trial. BMJ Open. 2018 Jul 19;8(7):e022412. doi: 10.1136/bmjopen-2018-022412. — View Citation
Deady M, Mills KL, Teesson M, Kay-Lambkin F. An Online Intervention for Co-Occurring Depression and Problematic Alcohol Use in Young People: Primary Outcomes From a Randomized Controlled Trial. J Med Internet Res. 2016 Mar 23;18(3):e71. doi: 10.2196/jmir.5178. — View Citation
Firth J, Torous J, Nicholas J, Carney R, Pratap A, Rosenbaum S, Sarris J. The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. World Psychiatry. 2017 Oct;16(3):287-298. doi: 10.1002/wps.20472. — View Citation
Firth J, Torous J, Nicholas J, Carney R, Rosenbaum S, Sarris J. Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. J Affect Disord. 2017 Aug 15;218:15-22. doi: 10.1016/j.jad.2017.04.046. Epub 2017 Apr 25. — View Citation
Gratz, K.L., Roemer, L. Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. J Psychopathol Behav Assess 30, 315 (2008). https://doi.org/10.1007/s10862-008-9102-4
Hassan AN, Howe AS, Samokhvalov AV, Le Foll B, George TP. Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis. Am J Addict. 2017 Sep;26(6):551-563. doi: 10.1111/ajad.12581. Epub 2017 Jul 4. — View Citation
Hogarth L, Hardy L, Bakou A, Mahlberg J, Weidemann G, Cashel S, Moustafa AA. Negative Mood Induction Increases Choice of Heroin Versus Food Pictures in Opiate-Dependent Individuals: Correlation With Self-Medication Coping Motives and Subjective Reactivity. Front Psychiatry. 2019 May 15;10:274. doi: 10.3389/fpsyt.2019.00274. eCollection 2019. — View Citation
Hyman SM, Fox H, Hong KI, Doebrick C, Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol. 2007 Apr;15(2):134-43. doi: 10.1037/1064-1297.15.2.134. — View Citation
Kay-Lambkin FJ, Baker AL, Lewin TJ, Carr VJ. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction. 2009 Mar;104(3):378-88. doi: 10.1111/j.1360-0443.2008.02444.x. — View Citation
Kenardy JA, Dow MG, Johnston DW, Newman MG, Thomson A, Taylor CB. A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial. J Consult Clin Psychol. 2003 Dec;71(6):1068-75. doi: 10.1037/0022-006X.71.6.1068. — View Citation
Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry. 1986 Aug;43(8):733-8. doi: 10.1001/archpsyc.1986.01800080019003. — View Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. — View Citation
Kroenke, Kurt, & Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, 32(9), 509-515. https://doi.org/10.3928/0048-5713-20020901-06
Krupnick JL, Green BL, Amdur R, Alaoui A, Belouali A, Roberge E, Cueva D, Roberts M, Melnikoff E, Dutton MA. An Internet-based writing intervention for PTSD in veterans: A feasibility and pilot effectiveness trial. Psychol Trauma. 2017 Jul;9(4):461-470. doi: 10.1037/tra0000176. Epub 2016 Sep 8. — View Citation
Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PM. Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. J Consult Clin Psychol. 2003 Oct;71(5):901-9. doi: 10.1037/0022-006X.71.5.901. — View Citation
Levin ME, Navarro C, Cruz RA, Haeger J. Comparing in-the-moment skill coaching effects from tailored versus non-tailored acceptance and commitment therapy mobile apps in a non-clinical sample. Cogn Behav Ther. 2019 May;48(3):200-216. doi: 10.1080/16506073.2018.1503706. Epub 2018 Aug 17. — View Citation
Maloney E, Degenhardt L, Darke S, Nelson EC. Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav. 2009 Sep;34(9):723-9. doi: 10.1016/j.addbeh.2009.04.011. Epub 2009 May 3. — View Citation
Marshall BDL, Green TC, Elston B, Yedinak JL, Hadland SE, Clark MA. The Effectiveness of Internet- and Field-Based Methods to Recruit Young Adults Who Use Prescription Opioids Nonmedically. Subst Use Misuse. 2018 Aug 24;53(10):1688-1699. doi: 10.1080/10826084.2018.1425725. Epub 2018 Jan 24. — View Citation
McHugh RK, Fitzmaurice GM, Carroll KM, Griffin ML, Hill KP, Wasan AD, Weiss RD. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend. 2014 Dec 1;145:121-6. doi: 10.1016/j.drugalcdep.2014.10.002. Epub 2014 Oct 16. — View Citation
Moore MT, Anderson NL, Barnes JM, Haigh EA, Fresco DM. Using the GAD-Q-IV to identify generalized anxiety disorder in psychiatric treatment seeking and primary care medical samples. J Anxiety Disord. 2014 Jan;28(1):25-30. doi: 10.1016/j.janxdis.2013.10.009. Epub 2013 Nov 20. — View Citation
Newman, M. G., Zuellig, A. R., Kachin, K. E., Constantino, M. J., Przeworski, A., Erickson, T., & Cashman-McGrath, L. (2002). Preliminary reliability and validity of the Generalized Anxiety Disorder Questionnaire-IV: A revised self-report diagnostic measure of generalized anxiety disorder. Behavior Therapy, 33(2), 215-233. https://doi.org/10.1016/S0005-7894(02)80026-0
Pani PP, Vacca R, Trogu E, Amato L, Davoli M. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD008373. doi: 10.1002/14651858.CD008373.pub2. — View Citation
Stathopoulou G, Pollack MH, Otto MW. Anxiety sensitivity moderates drug cravings in response to induced negative affect in opioid dependent outpatients. Addict Behav. 2018 Sep;84:75-78. doi: 10.1016/j.addbeh.2018.03.020. Epub 2018 Mar 13. No abstract available. — View Citation
Stein MD, Santiago Rivera OJ, Anderson BJ, Bailey GL. Perceived need for depression treatment among persons entering inpatient opioid detoxification. Am J Addict. 2017 Jun;26(4):395-399. doi: 10.1111/ajad.12554. Epub 2017 Apr 28. — View Citation
Walker J, Burke K, Wanat M, Fisher R, Fielding J, Mulick A, Puntis S, Sharpe J, Esposti MD, Harriss E, Frost C, Sharpe M. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychol Med. 2018 Oct;48(14):2285-2298. doi: 10.1017/S0033291718000624. Epub 2018 Mar 26. — View Citation
Watkins KE, Hunter SB, Wenzel SL, Tu W, Paddock SM, Griffin A, Ebener P. Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment. Am J Drug Alcohol Abuse. 2004 Nov;30(4):749-64. doi: 10.1081/ada-200037538. — View Citation
Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). J Correct Health Care. 2015 Jan;21(1):12-26. doi: 10.1177/1078345814557513. Erratum In: J Correct Health Care. 2020 Apr;26(2):194. — View Citation
Wilhelm S, Weingarden H, Ladis I, Braddick V, Shin J, Jacobson NC. Cognitive-Behavioral Therapy in the Digital Age: Presidential Address. Behav Ther. 2020 Jan;51(1):1-14. doi: 10.1016/j.beth.2019.08.001. Epub 2019 Aug 8. — View Citation
* Note: There are 34 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale | Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity | at baseline, up to 3 days after enrollment | |
Primary | Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale | Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity | 4 weeks after enrollment | |
Primary | Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale | Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity | 8 weeks from enrollment | |
Primary | Change in depressive symptoms as assessed by Patient Health Questionnaire-9 | Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day) | at baseline, up to 3 days after enrollment | |
Primary | Change in depressive symptoms as assessed by Patient Health Questionnaire-9 | Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day) | 4 weeks after enrollment | |
Primary | Change in depressive symptoms as assessed by Patient Health Questionnaire-9 | Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day) | 8 weeks from enrollment | |
Primary | Positive Test for Opioids | urine tests will detect substance use in participants | at baseline, up to 3 days after enrollment | |
Primary | Positive Test for Opioids | urine tests will detect substance use in participants | 2 weeks after enrollment | |
Primary | Positive Test for Opioids | urine tests will detect substance use in participants | 4 weeks after enrollment | |
Primary | Positive Test for Opioids | urine tests will detect substance use in participants | 6 weeks after enrollment | |
Primary | Positive Test for Opioids | urine tests will detect substance use in participants | 8 weeks after enrollment | |
Secondary | Opioid Dependency using the Rapid Opioid Dependence Screen | The RODS is an eight-item questionnaire inquiring about tolerance; withdrawal; unintended dosage or duration of use; persistent desire and unsuccessful quit attempts; time spent obtaining using and recovering from opioid use. | at baseline, up to 3 days after enrollment | |
Secondary | Opioid Dependency using the Opioid Craving Scale | The Opioid Craving Scale measures opioid cravings using three questions: (1) "How much do you currently crave opiates" (0 Not at all - 10 Extremely). | at baseline, up to 3 days after enrollment | |
Secondary | Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS) | Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always) | at baseline, up to 3 days after enrollment | |
Secondary | Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS) | Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always) | 4 weeks after enrollment | |
Secondary | Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS) | Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always) | 8 weeks after enrollment | |
Secondary | Self Regulation Scale | 12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely) | at baseline, up to 3 days after enrollment | |
Secondary | Self Regulation Scale | 12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely) | 4 weeks after enrollment | |
Secondary | Self Regulation Scale | 12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely) | 8 weeks after enrollment | |
Secondary | Estimates of Activities | Use mobile sensor and phone utilization data to develop individualized estimates of activities. | 56 days (or 8-weeks) | |
Secondary | Estimates of sociability | Use mobile sensor and phone utilization data to develop individualized estimates of sociability | 56 days (or 8-weeks) | |
Secondary | Estimates of Light Exposure | Use mobile sensor and phone utilization data to develop individualized estimates of light exposure. | 56 days (or 8-weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03535805 -
Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Recruiting |
NCT05419934 -
EMDR Therapy in Young Children, a Double-blinded Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT04136054 -
Better Sleep in Psychiatric Care - Anxiety and Affective Disorders
|
N/A | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT04647318 -
Physiological Response to Self-compassion Versus Relaxation
|
N/A | |
Active, not recruiting |
NCT05114824 -
Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students
|
N/A | |
Recruiting |
NCT05843695 -
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
|
N/A | |
Completed |
NCT05078450 -
Mood Lifters Online for Graduate Students and Young Professionals
|
N/A | |
Not yet recruiting |
NCT06162624 -
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
|
N/A | |
Not yet recruiting |
NCT05863637 -
Intensive Short-Term Dynamic Psychotherapy (ISTDP) for Anxiety Diagnoses in a Primary Care Setting
|
N/A | |
Not yet recruiting |
NCT05747131 -
Emotion Detectives In-Out: Feasibility and Efficacy of a Blended Version of the Unified Protocol for Children
|
N/A | |
Not yet recruiting |
NCT05225701 -
Efficacy of a Transdiagnostic Guided Internet-Delivered Intervention for Emotional, Trauma and Stress-Related Disorders.
|
N/A | |
Completed |
NCT02579915 -
Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
|
N/A | |
Recruiting |
NCT02376959 -
Effect of Spiritist "Passe" Energy Therapy in Reducing Anxiety in Volunteers
|
N/A | |
Recruiting |
NCT02186366 -
Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type
|
N/A | |
Not yet recruiting |
NCT02126787 -
Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment
|
N/A | |
Completed |
NCT02134730 -
School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial
|
N/A | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT01333098 -
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
|
Phase 1/Phase 2 |